Ischaemic stroke is associated with an excessive release of glutamate in brain. GOT (glutamate-oxaloacetate transaminase) and GPT (glutamate-pyruvate transaminase) are two enzymes that are able to metabolize blood glutamate facilitating the lowering of extracellular levels of brain glutamate. Our aim was to study the association between blood levels of both enzymes and stroke outcome in patients with acute ischaemic stroke. We prospectively studied 365 patients with first ischaemic stroke<12 h. Glutamate, GOT and GPT levels were determined in blood samples obtained at admission. We considered functional outcome at 3 months [good outcome: mRS (modified Rankin Scale)≤2; poor outcome mRS >2], END (early neurological deterioration) in the first 72 h [increment ≥4 points in NIHSS (National Institutes of Health Stroke Scale)] and infarct volume [CT (computed tomography) at 36–72 h] as end points. We have found an inverse correlation between GOT and GPT levels and blood glutamate levels. Patients with poor outcome showed lower levels of GOT (11.9±8.2 compared with 22.7±10.2 m-units/ml, P<0.0001) and GPT (19.5±14.3 compared with 24.7±20.3 m-units/ml; P=0.004). A negative correlation has been found between GOT (Pearson coefficient=−0.477, P<0.0001) and GPT (Pearson coefficient=−0.116; P=0.027) levels and infarct volume. Patients with END showed higher levels of blood glutamate (381.7±97.9 compared with 237.6±114.0 μmol/l, P<0.0001) and lower levels of GOT (10.8±6.7 compared with 18.1±10.8 m-units/ml; P<0.0001). This clinical study shows an association between high blood GOT and GPT levels and good outcome in ischaemic stroke patients, this association being stronger for GOT than GPT levels.
Skip Nav Destination
Article navigation
Research Article|
March 18 2011
Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels
Francisco Campos;
Francisco Campos
1
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
Manuel Rodríguez-Yáñez;
Manuel Rodríguez-Yáñez
1
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
Mar Castellanos;
Mar Castellanos
†Department of Neurology-Stroke Unit, Biomedical Research Institute of Girona, Hospital Universitario Doctor Josep Trueta, Girona, Spain
Search for other works by this author on:
Susana Arias;
Susana Arias
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
María Pérez-Mato;
María Pérez-Mato
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
Tomás Sobrino;
Tomás Sobrino
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
Miguel Blanco;
Miguel Blanco
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Search for other works by this author on:
Joaquín Serena;
Joaquín Serena
†Department of Neurology-Stroke Unit, Biomedical Research Institute of Girona, Hospital Universitario Doctor Josep Trueta, Girona, Spain
Search for other works by this author on:
José Castillo
*Department of Neurology-Stroke Unit, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain
Correspondence: Professor José Castillo (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
August 17 2010
Revision Received:
January 05 2011
Accepted:
January 26 2011
Accepted Manuscript online:
January 26 2011
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2011 Biochemical Society
2011
Clin Sci (Lond) (2011) 121 (1): 11–17.
Article history
Received:
August 17 2010
Revision Received:
January 05 2011
Accepted:
January 26 2011
Accepted Manuscript online:
January 26 2011
Citation
Francisco Campos, Manuel Rodríguez-Yáñez, Mar Castellanos, Susana Arias, María Pérez-Mato, Tomás Sobrino, Miguel Blanco, Joaquín Serena, José Castillo; Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 1 July 2011; 121 (1): 11–17. doi: https://doi.org/10.1042/CS20100427
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.